Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity.Quambusch, L., Landel, I., Depta, L., Weisner, J., Uhlenbrock, N., Muller, M.P., Glanemann, F., Althoff, K., Siveke, J.T., Rauh, D.
(2019) Angew Chem Int Ed Engl 58: 18823-18829
- PubMed: 31584233
- DOI: https://doi.org/10.1002/anie.201909857
- Primary Citation of Related Structures:
- PubMed Abstract:
Isoforms of protein kinase Akt are involved in essential processes including cell proliferation, survival, and metabolism. However, their individual roles in health and disease have not been thoroughly evaluated. Thus, there is an urgent need for perturbation studies, preferably mediated by highly selective bioactive small molecules. Herein, we present a structure-guided approach for the design of structurally diverse and pharmacologically beneficial covalent-allosteric modifiers, which enabled an investigation of the isoform-specific preferences and the important residues within the allosteric site of the different isoforms. The biochemical, cellular, and structural evaluations revealed interactions responsible for the selective binding profiles. The isoform-selective covalent-allosteric Akt inhibitors that emerged from this approach showed a conclusive structure-activity relationship and broke ground in the development of selective probes to delineate the isoform-specific functions of Akt kinases.
Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Research Center (DKFZ), Heidelberg, Germany.